{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.8","value":"62.5"},{"groupId":"OG001","spread":"22.9","value":"66.5"},{"groupId":"OG002","spread":"24.2","value":"63.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"91"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.9","value":"15.6"},{"groupId":"OG001","spread":"12.9","value":"13.1"},{"groupId":"OG002","spread":"14.2","value":"14.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"69"}],"units":"Participants"}],"title":"Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.5","value":"14.4"},{"groupId":"OG001","spread":"13.4","value":"12.0"},{"groupId":"OG002","spread":"17.3","value":"13.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"55"}],"units":"Participants"}],"title":"Week 49"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"91"}],"units":"Participants"}],"description":"Range of motion (ROM) of the joint was assessed by a qualified, independent, and blinded or third-party assessors at the clinical site. Measurements were recorded in degrees. At baseline, the plane of movement with the smallest relative value (worst) was identified and this plane was used for evaluating the relative change of motion subsequently. Only the plane with the worst impaired ROM at baseline was selected for subsequent analyses.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received treatment of Pexidartinib,1000 mg (5 capsules per day) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks and also received Pexidartinib in Part 2 at their prescribed dose.\n\nPexidartinib: Each capsule contains 200 mg of Pexidartinib for oral administration.","id":"OG000","title":"Pexidartinib Part 1 and Part 2"},{"description":"Participants received treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks in Part 1 and also received Pexidartinib in Part 2 at their prescribed dose.\n\nPlacebo: Placebo capsule matching Pexidartinib capsule for oral administration Pexidartinib: Each capsule contains 200 mg of Pexidartinib for oral administration.","id":"OG001","title":"Placebo Part 1, Pexidartinib Part 2"},{"description":"All participants who received Pexidartinib in Part 1 and Part 2 as well as those who only received Pexidartinib in Part 2.","id":"OG002","title":"All Pexidartinib Treated"}],"paramType":"MEAN","populationDescription":"Range of Motion (ROM) was assessed in the ITT population.","reportingStatus":"POSTED","timeFrame":"By Week 49","title":"Mean Change From Baseline For Range of Motion (ROM) Score in Participants Receiving Pexidartinib Compared With Those on Placebo by Week 49","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"degrees"}